Coffee Consumption and Improved Liver Outcomes: Clinical, Imaging, and Proteomic Evidence From the UK Biobank

By afschroeder • July 2, 2026

Kim HS, Rezaee-Zavareh MS, Wang Y, Attia AM, Kwak M, Burm S, Celtik D, Legaspi D, Khattab O, Kim N, Mengistu BM, Larios KN, Kim DS, Ayoub W, Kuo A, Martin P, Vipani A, Wang Y, Liangpunsakul S, Li D, Lu SC, Pandol S, Yang JD. Coffee Consumption and Improved Liver Outcomes: Clinical, Imaging, and Proteomic Evidence From the UK Biobank. Clin Gastroenterol Hepatol. 2026 Jul 1:S1542-3565(26)00404-0. doi: 10.1016/j.cgh.2026.04.035. Epub ahead of print. PMID: 42385787.

Tags: Cedars Sinai DoM, Cirrhosis, Coffee Consumption, Digestive Diseases, Hepatocellular carcinoma, Liver disease, Publications, UK Biobank

Related Posts

Association of Eicosanoids and Eicosanoid-Related Metabolites With Obesity and Cardiometabolic Traits

Chitsazan M, Parekh JK, Grundmann AL, Lau ES, Alotaibi M, Yu B, Rebholz CM, Selvin E, Allen NB, Allison MA, Jain M, Cheng S, Ho[...]

Nirmatrelvir-ritonavir targeting viral persistence in post-COVID-19 condition (long COVID) in the USA (RECOVER-VITAL): a randomised, double-blind, placebo-controlled, phase 2 trial

Baden LR, Shah NS, Liu STH, Cohen J, Moy J, Kumar A, McComsey GA, Chen P, Floris-Moore M, Singer NG, Fernandez I, Slandzicki AJ, Wiley[...]

L-Glutamine in combination with first-line gemcitabine and nab-paclitaxel in advanced pancreatic ductal adenocarcinoma: an open-label, single-arm, phase 1 GlutaPanc trial

Gong J, Muranaka H, Choi SY, Tighiouart M, Bhute S, Aja ER, Jacobs JP, Stotland A, Van Eyk J, Elmadbouh OHM, Edderkaoui M, Tanaka S,[...]